Portal de Periódicos da CAPES

Penems: In Vitro and In Vivo Experiments

1988; Wiley; Volume: 28; Issue: 2 Linguagem: Catalão

10.1002/j.1552-4604.1988.tb05736.x

1552-4604

O. Zák, Marc Lang, Robert Cozens, E. A. Kónopka, Helmut Mett, Peter Schneider, W. TOSCH, Riccardo Scartazzini,

Advancements in Transdermal Drug Delivery

The Journal of Clinical PharmacologyVolume 28, Issue 2 p. 128-135 Penems: In Vitro and In Vivo Experiments Oto Zak, Corresponding Author Oto Zak Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Pharmaceuticals Division, Ciba-Geigy Ltd., 4002 Basle, Switzerland.Search for more papers by this authorMarc Lang, Marc Lang Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorRobert Cozens, Robert Cozens Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorEdward A. Konopka, Edward A. Konopka Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorHelmut Mett, Helmut Mett Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorPeter Schneider, Peter Schneider Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorWerner Tosch, Werner Tosch Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorRiccardo Scartazzini, Riccardo Scartazzini Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this author Oto Zak, Corresponding Author Oto Zak Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Pharmaceuticals Division, Ciba-Geigy Ltd., 4002 Basle, Switzerland.Search for more papers by this authorMarc Lang, Marc Lang Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorRobert Cozens, Robert Cozens Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorEdward A. Konopka, Edward A. Konopka Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorHelmut Mett, Helmut Mett Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorPeter Schneider, Peter Schneider Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorWerner Tosch, Werner Tosch Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this authorRiccardo Scartazzini, Riccardo Scartazzini Pharmaceuticals Division, Ciba-Geigy Limited, 4002 Basle, Switzerland.Search for more papers by this author First published: February 1988 https://doi.org/10.1002/j.1552-4604.1988.tb05736.xCitations: 13AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Hoover JRE: Structure-activity relationship in antibiotics containing the β-lactam structure, in AL Demain, NA Solomon (eds): Handbook of Experimental Pharmacology, vol. 67/II. New York, Springer Verlag, 1983; 119– 245. 2 Ernest I: The penems, in RB Morrin, M Gorman (eds): Chemistry and Biology of β-lactam Antibiotics, Vol 2. London, Academic Press, 1982; 315– 360. 3 Woodward RB: Recent advances in the chemistry of β-lactam antibiotics, in J Eiks (ed): Recent Advances in the Chemistry of β-lactam Antibiotics. London, The Chemical Society Burlington House; 1977; 167– 180. 4 Hajdu R, Hayase K, Sundelof J, et al: Cilastatin-sensitive lactamase active on carbapenem and penem antibiotics, in J Ishigami (ed): Recent Advances in Chemotherapy, Antimicrobial Section 2. Tokyo, University of Tokyo Press, 1985: 1211– 1212. 5 Matsuda K, Sazaki K, Inoue K, et al: In vitro antibacterial activity of Sch 34 343 and its stability to β-lactamases and renal dehy-dropeptidase 1. Antimicrob Agents Chemother 1985; 28: 684– 688. 6 Chung M, Radwanski E, Loebenberg D, et al: Interspecies pharmacokinetic scaling of SCH 34 343. J Antimicrob Chemother 1985; 15(suppl C): 227– 233. 7 Kahan FM, Kropp H, Sundelof JG, Birnbaum J: Thienamycin: Development of imipenem-cilastatin. J Antimicrob Chemother 1983; 12(suppl D): 1– 35. 8 Neu HC, Chin NX, Labthavikul P: In vitro activity and β-lactamase stability and inhibitory properties of a new penem antibiotic, Sch 34 343. J Antimicrob Chemother. 1985; 15(suppl C): 25– 37. 9 Reeves DS, Holt HA, Bywater MJ: Comparative in vitro activity of Sch 34 343, a new penem antibiotic. J Antimicrob Chemother 1985; 15(suppl C): 57– 66. 10 Markowitz N, Pohlod DJ, Saravolatz LD, Quinn EL: In vitro susceptibility patterns of methicillin-resistant and -susceptible Staphylococcus aureus strains in a population of parenteral drug abusers from 1972 to 1981. Antimicrob Agents Chemother 1983; 23: 450– 457. 11 Witte JL, Sapico FL, Canawati HN: In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin. Antimicrob Agents Chemother 1982; 22: 906– 908. 12 Tuomanen E., Gilbert K., and Tomasz A. 1985. β-Lactam antibiotics which kill nongrowing bacteria in vitro and in vivo. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Program and Abstracts, Abstract No. 993. 13 Zak O, Sande MA: Correlation of in vitro antimicrobial activity of antibiotics with results of treatment in experimental animal models and human infection, in LD Sabath (ed): Action of Antibiotics in Patients. Bern, Hans Huber 1982; 55– 67. 14 Bruna C Della, Jabés D, Sebben G, Sanfilippo A: In vitro and in vivo evaluation of the penem FCE 22 101 and its orally absorbed ester FCE 22 891. G Ital Chemioter 1983; 30: 125– 130. 15 Loebenberg D, Miller GH, Moss EL Jr, et al: Evaluation of the in-vivo activity of SCH 29 482. J Antimicrob Chemother 1982; 9(suppl C): 221– 231. 16 Loebenberg D, Moss EL Jr, Rudeen J, et al: Evaluation of the in vivo efficacy of SCH 34 343. J Antimicrob Chemother 1985; 15(suppl C): 207– 218. 17 Wells CL, Arland LA, Simmons RL, Rotstein OD: In vivo bactericidal activity of SCH 34 343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses. J Antimicrob Chemother 1985; 15(suppl C): 199– 206. 18 Lang M, Schneider P, Tosch W, et al: Penems: A new class of β-lactam antibiotics: Synthesis and in vitro antimicrobial activity of 2-(N-azolyl)alkyl derivatives. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Program and Abstracts. Abstract no. 376. 19 Norrby SR, Jonsson M: Comparative in vitro antibacterial activity of Sch 34 343, a novel penem antibiotic. Antimicrob Agents Chemother 1985; 27: 128– 131. 20 Neu HC, Chin NX, Labthavikul P: The in vitro activity of a novel penem FCE 22 101 compared to other β-lactam antibiotics. J Antimicrob Chemother 1985; 16: 305– 313. 21 Neu HC, Labthavikul P: Antibacterial activity of an oral penem, Sch 29 482. J Antimicrob Chemother 1982; 9(suppl C): 49– 57. 22 Wise R, Andrews JM, Danks G: Comparison of in vitro activity of FCE 22 101, a new penem, with those of other β-lactam antibiotics. Antimicrob Agents Chemother 1983; 24: 909– 914. 23 Barry AL, Jones RN, Wilson HW, et al: Sch 29 482, a new oral penem: Comparative in-vitro activity, β-lactamase stability and inhibition. J Antimicrob Chemother 1982; 9(suppl C): 97– 112. 24 Jones RN, Barry AL, Fuchs PC, Thornsberry C: In vitro evaluation of Sch 34 343: Antimicrobial activity, β-lactamase stability and inhibition. J Antimicrob Chemother 1985; 15(suppl C): 99– 109. Citing Literature Volume28, Issue2February 1988Pages 128-135 ReferencesRelatedInformation